🇮🇳IN
Sign In
MA

MANGALAM

NSE

Mangalam Drugs And Organics Limited

₹27.49

-1.07(-3.75%)
FSI

Fundamental Strength Index

computed from the statements below↑ higher is better

Weights come from configuration, not from this page — each pillar links to the section below that explains it.

Income stmtHistory

Profitability

headline ratios

Growth

compounded, from filed annual results

Segment Results

₹ Cr

Working Capital & Efficiency

days · ROCE %

MANGALAM financial summary

For Mar 2026, Mangalam Drugs And Organics Limited reported revenue of ₹232 crore, which fell 27.0% from the previous year. Net profit was -₹44 crore, which fell 728.6% year on year, on an operating margin of -6%. Earnings per share came in at -₹27.68. Over the 5 years from Mar 2021 to Mar 2026, revenue changed at a compound annual rate of -9.4%. The highest operating margin in that period was 14% in Mar 2021. Annual results are available for 14 financial years, from Mar 2013 to Mar 2026.

Revenue₹232 crore
Net profit-₹44 crore
Operating margin-6%
EPS-₹27.68

Investment in securities market are subject to market risks. Read all the related documents carefully before investing. Disclaimer